Mirai Bio Advances In Vivo CAR-T Platform at ASGCT
CAMBRIDGE, Mass., May 12, 2026 Mirai Bio unveiled new preclinical data at the American Society of Gene and Cell...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
CAMBRIDGE, Mass., May 12, 2026 Mirai Bio unveiled new preclinical data at the American Society of Gene and Cell...
CAMBRIDGE, Mass., April 27, 2026 Sail Biomedicines announced it will present new preclinical data supporting its In Vivo eRNA™...
Rochester, Minnesota | December 23, 2025 — Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies, announced the...
PALO ALTO, CA., June 30, 2025 — BridgeBio Pharma, Inc. (Nasdaq: BBIO), the biopharmaceutical company dedicated to developing transformative...
Lake Worth, FL. & New York, August 23, 2025 – Thomas H. Lee Partners (THL) has entered into a...
August 8, 2025 — London, UK. BioNTech SE has reached an agreement with CureVac to receive a non-exclusive license...
NORTH CHICAGO, IL. and SAN DIEGO, CA, August 19, 2025 – AbbVie (NYSE: ABBV) and Capstan Therapeutics, Inc. (“Capstan”),...
